DRI-DPRE-Prague-presentee25052007

1Prague, May 25th 2007

InsermInsermFrench National Institute of Health

andMedical Research

•Created in 1964 from the National Institute of Hygiene and Hospital Research

•Working through the Ministries for Research and Health


Inserm : key figures

Budget 2007 : 700 M€Total staff: 13 000

(2 500 physicians) of which 4900 Inserm employees: 2100 scientists and 2800

technical staff (62% of total budget dedicated to salaries)

335 Inserm laboratories19 research centers

374 French and foreign firms are partners of Inserm

An active patent portfolio of 572 families

41 Clinical Investigation Centers (CIC)

56 start-up companies based on Inserm technology


What is Inserm ?

The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health

All fields of research are covered in these domains

90% of the 365 research units are located in University hospitals Research units with 8 years mandate with mid-term (4 year)

evaluation. Stringent evaluation

Investigator- driven projects - AVENIR programme

Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.


The Inserm performance

about:blank


OrganizationOrganization Bottom-up initiatives: selection based on Bottom-up initiatives: selection based on

quality quality and innovationand innovation

Networks focused on major public health Networks focused on major public health issues: “National Research Programs”:issues: “National Research Programs”:- Diabetes, Cardiovascular, Hepato-Gastro- Diabetes, Cardiovascular, Hepato-Gastro-

EnterologyEnterology- Bone and joint diseases, endocrinolgy and Bone and joint diseases, endocrinolgy and

reproduction etc…. reproduction etc….


Bone and Joint Diseases

2.2%

Diabetes2.6%

Hepatitis 3.1%

Genetic diseases

10.5%

16.8%Cancer

Cardiovascular diseases

9.1%

17.1%Immunology

of which 9.3%for neurologic disorders

20.6%

Neurosciences

Infectious diseasesand microbiology

(without Aids and Hepatitis)

8.3%

Public health7.5%

Handicap5.1%

Nutrition4.8% AIDS

3.7%

Research laboratories being often involved in more than one domain, the overall distribution is over 100 %


Research organizations CNRS, CEA, Inra, Inria, IRD,

Pasteur Institute, Curie Institute

Scientific & medical societies, Patients

associations, Foundation, Charities

Universities Industry

National research & Public health

agencies

Hospitals

International scientific

community


Inserm : creation of research centers

Objectives and main characteristics:• Critical mass (100 to 300 staffs),• Mutualisation and Integration• International visibility, Attractiveness

Assessment criteria:• Scientific excellence• Quality of the management :

Governing structure, mutualised administration & managementTechnology transfert and research outcomes

Sharing of technical facitiliesCoordination of scientific events and programmesImplementation of research training programmesInternational scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)


19 Research Centers in 2007

Some exemples: 1- Paris 6, Pluri-thematic2- Paris 6, Neurophysiology4- Paris 5, Pluri-thematic5- Créteil, Pluri-thematic6- Lilles, Pluri-thematic7- Dijon, Cancer/Nutrition8- Bordeaux, Neurophysiology9- Grenoble, Neurophysiology10- Grenoble, Cancer11- Toulouse, Pluri-thematic


Facilities- Histology - Cellular imaging- Human neurogenetics- Experimental pharmacology- Cellular and animal models

Thematics- Pathophysiological studies and therapeutic innovation in neurosciences- Sensory diseases : auditio, vision, propriceptionnociception

Partners- Montpellier 1 et 2 Universities- Montpellier University Hospital- Inserm

Physiopathologie et thérapie des déficits sensoriels et moteurs

Technology transfer- Public-private Partnerships - patents

Director : Christian Hamel

www.inmfrance.com

Inserm Unit 5835 teams

108 staffs Montpellier


Institut François MagendieDirector : Pier Vi Piazza

Facilities- Small animals- Non human primate- Motricity- IRM- Biochemestry

Technology transfer- Public-private Partnerships

Thematics- Addictiopn physiopathology- Neurogenesis and physiopathology- Physiology of the neuro-endocrinal systems- Synaptic plasticity and medullar neuronal netkwork physiopathology

Partners- Bordeaux 1 University- Bordeaux University Hospital- Inserm


100 staffs Bordeaux

3 Avenir program


Département de Recherche en CancérologieDReC

Director : Marc Bonneville


145 staffs Nantes

Facilities- Quantitative PCR- Cellular imaging- Recombinant proteins- Histology, morphology

Thematics- Lymphocyte and dendritic cells - Cytokines and receptors - Conventional and non-conventional immunity,Oncology, virology- Apoptosis and tumor progression- Radiopharmaceutics

Partners- Inserm - Nantes University Hospital - Nantes University

Technology transfer- 14 patents- Public-private Partnerships

www.u601.nantes.inserm.fr


Institut de Médecine Moléculaire de RangueilI2MR

Director : Angelo Parini

Facilities- Biotherapy- Proteomics- Histo-morphology- Genomics and molecular biology- Fonctional exploration - Zootechnics

Thematics- Obesity, heart and kidney pathologies- Vascular biology, inflammation and diabetes- Epithelial cancers, angiogenesis and signalling

Partners- Inserm - Toulouse University Hospital - Paul Sabatier University in Toulouse

Technology transfer - Public-private Partnerships


156 staffs Toulouse


Centre de recherche Cardiovasculaire InsermCRCIL

Director : Bernard Lévy


114 staffs Paris

Facilities- Animals- Cell Culture- Cytometry- Small animal fonctional exploration

Thematic- Cardiovascular- Angiogenesis

Partners- Inserm - Paris University Hospital- Paris 7 University



Inserm Unit 73311 teams 160 staffs

Paris

Facilities- Quantitative PCR- Cellular imaging- Small animal Fonctional explorations - Histology, morphology

Thematics- Gastroenterology- Inflammation- Receptors

Partners- Inserm - Paris University Hospital- Paris 7 University

Director : Marc Laburthe



Facilities- Transcriptomics- Proteomics- Photonic Imaging- Pharmacology

Inserm Unit 6615 departments

159 staffs Montpellier

1 Avenir program

Thematics- Cancer- Cardiovascular- Genetic and cellular therapies- Metabolism, endocrinology, nutrition- Human health- Brain

Partners- Inserm - Montpellier 1 et 2 Universities- Montpellier University Hospital - CNRS


* Sanofi* Pfizer* ….

Director : Joël Bockaert

www.igf.cnrs.fr


Inserm Unit 5967 departments

550 staffs Strasbourg

3 Avenir programs

Facilities- Cellular imaging- DNA microarray platform- Monoclonal Antibody- Structural biology- Bio-informatic- Protéomics

Thematics- Molecular pathology- Developmental and physiological gentics - Fonctional genomics- Cellular biologie and signal transduction- Molecular neurobiology

Partners- Inserm - Louis Pasteur University- CNRS

Technology transfer- > 20 contrats with industries- Public-private Partnerships

Director : D.Moras

www-igbmc.u-strasbg.fr


Research infrastructures

• National Genomic Research Consortium: CNRG National Sequencing Center National Genotyping Center Regional Genopoles Core Facilities • Biosafety-level 4 laboratory

• Local and regional technological plateforms

• Clinical Research Infrastructures


Main Inserm’s priorities

1. « Researchers » : Careers, Training & Mobility

2. To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach

3. To establish Inserm in a European and International context

4. To develop public/private partnerships


Career tracks at Inserm

• Junior, temporary contract (5 years with a 3-year intermediate evaluation), high level (research director) contracts

Avenir programEuropean programs: EURYI, ERC

• Permanent positions for senior scientists


AVENIR Programme

• Eligibility: Young scientists with permanent or temporary position, clinicians

• Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities

• Each successful candidate is allocated:

• A yearly budget of 60 K euros

• Minimum lab space of 50 m2

• Personnel: 1 post-graduate collaborator and 1 graduate student

• Each successful young scientist receives a salary for 5 years


ERC - European Research Council

The 7th FP - EU• Programme dedicated to

“Frontier research”• Targeted to:

– Young researchersStarting Independent Research Grant – Advanced researchersAdvanced Investigator Research Grant

• 100 to 400 K€/year up to 5 years

• Attractive research environment at Inserm:– 335 Research units incl.

19 Research centers– Performing research

infrastructures incl. 41 Clinical Reserach Centers

• Public-Private partnerships - Innovation

• Salary up to 7k€ monthly• Potential tenure career track


Interface contracts : General principles

• Based on :a permanent position + temporary, 3-5 year contracts

• To reinforce interactions with partners and mobility

- Hospitals: clinical research, medical issues- Health agencies: health policy issues- Universities: teaching, making scientific

information available to the society

• Industry: technological transfer and valorisation

• European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)


Interface contracts for Inserm scientists :Tenure position + 3-5 year contracts: " 2/3 – 1/3 "

Tenuredscientists

Hospital

Internationalinstitutions

Sanitary Agencies

« Internal » Inserm

UniversityIndustry


Interface Contract grants for MDs

• Reinforce research activities of clinicians and university research assistants and professors

• 3-5 year contracts for clinicians : assistant professors and professors, university employees

• Grant paid by Inserm to hospitals and universities to be used for : - clinical and teaching activities: temporary positions - financing research activities


Interface contracts for MDs

HOSPITALINSERM

UNIVERSITYINSERM


Joint post-doctoral career trackInserm-NIH

• 3-year post-doctoral positions in NIH: Join selection by Inserm and NIH

• Evaluation at the end of post-doctoral fellowship

• Junior, 5-year Inserm contract

• Tenure: Inserm, CNRS, University, industry etc ..


The School of InsermThe School of Inserm

A 3-year Theoretical and Practical Education which leads to a Master’s

• First year of Inserm School - Second year of Medical School :

Special School Intensive Training Session in February

June: Competitive Exam

• Second year of Inserm School - Third year of Medical School

6 month full time Research Clerkship in an Inserm Research Laboratory

• Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree


Clinical research and Translational research strategy


BasicResearch

Preclinical studies : Proof of concept

Inserm Inserm

[CRC]

Inserm

Phases IIb-III

Phase IVCohorts

Clinical trialsClinical trials

Proof of conceptPhases I-IIaBiotherapy


Clinical research infrastructures

2006 2001 2002 2003 2004 2005

Clinical research centers 41 17 21 28 31 41

Tissues Banks 47 16 30 47 47 47

Cohorts 118 131 135 142 147 147

Registries 35 17 29 29 31 35

Networks 22 9 22 22 22 22


FranceInserm

Spain SCReN

SwedenSweCRIN

GermanyKKS

DenmarkDCRIN

ItalyIRFMN & CIRM

HungaryHECRIN

UKUKCRN

Ireland ICRIN

EFGCP

National networks of Clinical Research Centres / Clinical Trial Units

AustriaATCRIN

SwitzerlandSCRN

EORTC

FinlandFinnCRIN

European Clinical Research Infrastructures Network, co-ordinated by INSERM:Pan-Europeaninfrastructure providing services to the preparation and the conduct of multinational clinical studies, with GMP facilities for biotherapy


• Science Case: A European network to coordinate European Scientific programs

and policies Clinical data and follow-up of patients and Healthy volunteers Innovative targets, biomarkers, clinical studies Technology transfer, dissemination of knowledge, valorisation

• Technical case: Repositories for qualified biological samples (DNA, RNA, proteins,

…), coupled to clinical data. Providers/distributors of samples within scientific project objectives Development of QA standards for European BRCs To store samples for the future (heritage) Distributed facilities / centralised database

Network of Biological Resources Facilities Cohorts of Patients


EU approach for of GMP Facilities

• Needs : to develop innovative “non-commercial” clinical trials - Lack of specific financial support

• Science Case: Reinforcing clinical research and translation of basic research to

therapy Production and evaluation of innovative therapeutic and

diagnostic agents : biomarkers and biotherapy / regenerative medicine : cell therapy, gene therapy, tissue engineering

• Technical case: Production of new therapeutic/diagnostic agents from

biotechnologies Products for Cell and Gene therapy Good Manufacturing Practices (GMO dissemination regulation), in

line with national legislation, able to cooperate across the borders Direct links with Clinical Research Centres (CRC - ECRIN)


IMI : Innovative Medicines for Europe

European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.

Inserm is the French representative in the Member states contact Group of IMI


Regional clustersRegional clusters

1.1. CanceropolesCanceropoles, , other thematic poles other thematic poles (Neuropole, …)(Neuropole, …)

2.2. CompetitivityCompetitivity clusters clusters (Industry)

3.3. Regional poles for research in Regional poles for research in

Neurosciences, etc.Neurosciences, etc.


Competitivity Clusters

Atlantic Biothérapies

Cancer Bio Santé

Prod’Innov

Lyonbiopôle Virology

Innovations thérapeutiques

Nutrition Santé Longévité

Medicen

Orpheme

Nutrition

International

National

Emergent

Imaging, Cancer, Biotehrapy, Neurosciences

Cancer Bio SantéRéunion

Qualitropic

67 created clusters 7 involving Inserm units


The European policy of Inserm


The main axes

EU Prospectives (ESF-EMRC, EUROHORCS,etc.)

Participation in European programmes : RTD FP & Public Health FP

Infrastructures - ESFRI (ECRIN, …)

Researchers’ mobility within EU programmes and

Bilateral actions: Common Research projects -Associated laboratories - Joint-units abroad


Multilateral cooperations’ actions

Participation to the European Research and Public Health programmes

Inserm andInserm andThe 6th Framework The 6th Framework

Programme of the EUProgramme of the EU

Inserm andInserm andThe 7th Framework The 7th Framework

Programme of the EUProgramme of the EU(2007 - 2013)(2007 - 2013)

QuickTime™ et undécompresseur TIFF (non compressé)sont requis pour visionner cette image.

• around 166 EU research projects• 26 in coordination (success rate: 50% last FP6 calls)

(preliminary data - April 2007)


International Cooperation Contracts (up to 4 years) Salary paid by “home” institution + additional salary

paid by “host” institution Reciprocal, bi-directional

=> Marie Curie « Co-fund » Programme (FP7)

Joint Post-doctoral training contracts

2 phases, commitment for a contractual recruitment when they return, bidirectional call for application

Prospectives towards Internationalisation of School of Inserm

European Mobility of Researchers« Towards a European Career Track »


Joint post-doctoral career track

• 3-year post-doctoral positions in host institutions: Joint selection with Inserm

Joint calls under preparation with European

institutions (ICL, Univ. Dundee, Porto…)

• Evaluation at the end of post-doctoral fellowship

• Junior, 5-year Inserm contract

• Tenure: Inserm, CNRS, University, industry etc ..


Cooperations between Inserm and Cooperations between Inserm and Czech Partners (1)Czech Partners (1)

43

20 cooperation projects undertaken since 2000=> more than 100 common publications (38 in 2006)

Main cities: Prague, Olomuc, Brno

Main Partner Institutions : Academy of Sciences of the Czech Republic, Charles University Prague, etc.

Main thematic areas : Neurosciences, Microbiology, Nutrition, Molecular Biology, Toxicology etc.

3 Czech Post-docs, Researchers and Fellows within Inserm's research units in 2006


European Associated Laboratory (EAL)

“Clinical Research on Obesity”

D. Langin, Toulouse – V. Stich, Charles University Prague

In the frame of the 6th EU Framework programme :

23 European research projects mainly in the LSH priority :

(7 NoEs - 12 IPs - 4 STREP) - 3 of them involved the EAL

Future collaborations within the FP7 :

Health priority, IMI, Infrastructures (ECRIN, BRCs)

44

Cooperations between Inserm and Cooperations between Inserm and Czech Partners (2)Czech Partners (2)


Bilateral cooperations’ tools:Associated Laboratories and Inserm’s Units abroad

Scientifically driven

8 years mandate with mid-term evaluation

Synergies: competencies and facility access

Co-funded by Inserm and Associated partner

Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)

Institutional “label”

Leverage effect for additional funding


BrusselsHeidelberg

Glasgow

Rome

Milan

Prague

Dundee

Barcelona

Porto

European Associated Laboratories (LEA)

Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)

Lille : M. Capron U547 / Brussels : M. Goldman (IMI)

Toulouse : AC Prats U589 / Dundee : JC Bourdon (Univ. Dundee)

Bordeaux: A. Bikfalvi E 113 / Milan: L. Bello (Univ. Degli Stuli)

Nice: G. Meneguzzi U 634 / Rome: G. Zambruno (IDI-IRCCS)

Villejuif: D. Samuel U 785 / Rome: M. Levrero (Univ. La Sapienza)

Montpellier: K. Ritchie U 888 / London: G. Thornicroft (King’s College of London)

Strasbourg: T. Baumert U 748 / Freiburg: H. Blum (Univ. of Freiburg)

Villejuif: T. Moreau U 780/ Barcelona: J. Antό (PRBB, IMIM-CREAL)

Bordeaux: L. Bordenave U 577 / Porto: M. Barbosa (IBMC, INEB)

London

Freiburg

Joint Research Unit in Europe:

Université de Glasgow / C. Doerig

U609

DKFZ / J. Rommelaere U701


Montréal

Pittsburgh

Rio de Janeiro

INSERM UnitAssociated LaboratoryIn preparation

Irvine

Montreal

Shanghai

Tokyo

Kyoto

SeoulNew York

NanjingDallas

BeijingHaïfa

Doha

Los Angeles

Buenos Aires

Laval

WuhanRabat

Guangzhou

Singapour


Inserm Transfert

• Inserm’s private subsidiary• Created in 2001, funded up to € 4,5 million• 60 people with scientific/industrial background

Missions:• Drive value creation from Inserm research• Allow an efficient partnering with the Industry• Ensure a fair economic return towards Inserm• Contribute to economic development

QuickTime™ et undécompresseur TIFF (LZW)

sont requis pour visionner cette image.


Development of services covering the whole technology transfer process :

• Detection of inventions / “coaching”• Protection of inventions & follow up / intellectual property management• Pre-technology transfer / Applied and Translational Research• Technology Transfer, collaborative and R&D agreements• Preclinical Development / Proof of Concept development• Industrial Partnerships / Clinical trials development• International and European projects management• Biotech start up coaching and funding (pre seed fund Inserm Transfert Initiative)• Legal and financial expertise

Proximity between both scientific and industrial communitiesfor a best partnership development

Integrated Technology Transfer Skills“From the bench to the partnering and the license”

InsermResearch

Intellectual Property License

Biotech start-up

Detection of Inventions




Inserm Transfert: Bridging the gap between Science and Business

INNOVATION

KNOW HOW

INSERM PARTNERS

RESEARCH

TEAMS

ADR

NewCo CreationSeed Fund

BusinessDevptIntellectual

Property

InternationalProjects

Sourcing

ValorisationCIC

GrantsConsortium

IndustrialPartnership- Collaboration- Licence

Spin-OffLegal

Finance




Key figures• 615 Patent families• 373 Companies interacting with Inserm• 481 License agreements• 546 Technology transfer contracts

• € 5,2 million/year of licensing income• € 15,4 million/year of R&D contracts

• 31 european and international projects under management• Total budget over € 200 million

• 11 biotech start-up created since 2001 that have raised above € 85 million euros near venture capitalists and financial partners




Contacts :Inserm’s web site : www.inserm.fr/en/inserm

Department of French Regional and European Strategic Policies

• Anne Bisagni, Director : [email protected]

• Philippe Arhets, Deputy Director : [email protected]

• Cécile Bergouignan, Bilateral cooperation :

[email protected]

Human Resources : Researchers task force

• Anne-Marie Laffaye, School of Inserm, Avenir :

[email protected]

• Richard Salives, Marie Curie Programme :

[email protected]

Documents

DRI-DPRE-Prague-presentee25052007